ISENTRESS raltegravir, Merck's First in Class Integrase Inhibitor, Reduced HIV Viral Load and Increased CD4 Cell Counts Through 96 Weeks in Treatment-Naive HIV-Infected Patients When Taken With Other Anti

ISENTRESS® (raltegravir), Merck & Co., Inc.’s first-in-class integrase inhibitor, in combination with two other anti-HIV medicines, reduced HIV viral load to undetectable levels (less than 50 copies/mL) in 83 percent of previously untreated (treatment-naive) HIV-infected patients which was comparable to that seen with efavirenz (Sustiva®/STOCRIN®)*, which reduced HIV viral load to undetectable levels in 84 percent of treatment-naive HIV-infected patients when also combined with the same anti-HIV medicines in patients through 96 weeks of treatment. Patients taking ISENTRESS experienced a mean increase in CD4 cell counts of 221 cells/mm3 without adverse impact on total or low-density...

Want to see the full article?

• Purchase this article for only $3.00